drugset / Trial / NCT00326131
A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The first purpose of this study is to determine how the body absorbs, metabolizes, and eliminates a single dose of BMS-275183 (labeled with radioactive carbon). Secondly, to measure the levels of BMS-275183 in your blood, study the safety of the drug, and to see what effects it has on your cancer.
Timeline
- Start
- 2006-04
- Primary completion
- 2007-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-275183 | Small molecule | — | Oral |